This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and (123)I-metaiodobenzylguanidine scintigraphy


Miyoshi, F., Ogawa, T., Kitao, S.- i., Kitayama, M., Shinohara, Y., Takasugi, M., Fujii, S., Kaminou, T.


AJNR. American Journal Of Neuroradiology, Volume: 34, No.: 11, Pages.: 2113-2118

Year of Publication



Background and Purpose: Progressive changes in the substantia nigra pars compacta and locus ceruleus of patients with Parkinson disease and Alzheimer disease visualized by neuromelanin MRI and cardiac postganglionic sympathetic nerve function on (123)I-metaiodobenzylguanidine scintigraphy have not been fully evaluated. We compared the diagnostic value of these modalities among patients with early Parkinson disease, late Parkinson disease, and Alzheimer disease.; Materials and Methods: We compared contrast ratios of signal intensity in medial and lateral regions of the substantia nigra pars compacta and locus ceruleus with those of the tegmentum of the midbrain and the pons, respectively, by use of neuromelanin MRI in patients with early Parkinson disease (n = 13), late Parkinson disease (n = 31), Alzheimer disease (n = 6), and age-matched healthy control subjects (n = 20). We calculated heart-to-mediastinum ratios on (123)I-metaiodobenzylguanidine scintigrams after setting regions of interest on the left cardiac ventricle and upper mediastinum.; Results: The signal intensity of the lateral substantia nigra pars compacta on neuromelanin MRI was significantly reduced in early and late Parkinson disease, and that of the medial substantia nigra pars compacta was gradually and stage-dependently reduced in Parkinson disease. The signal intensity of the locus ceruleus was obviously reduced in late Parkinson disease. Signal reduction was not significant in the substantia nigra pars compacta and locus ceruleus of patients with Alzheimer disease. The heart-to-mediastinum ratio on (123)I-metaiodobenzylguanidine scintigrams was stage-dependently reduced in Parkinson disease and normal in Alzheimer disease. The signal intensity ratios in substantia nigra pars compacta and locus ceruleus on neuromelanin MRI positively correlated with the heart-to-mediastinum ratio on (123)I-metaiodobenzylguanidine scintigrams.; Conclusions: Both neuromelanin MRI and (123)I-metaiodobenzylguanidine scintigraphy can help to evaluate disease progression in Parkinson disease and are useful for differentiating Parkinson disease from Alzheimer disease.;

Bibtex Citation

@article{Miyoshi_2013, doi = {10.3174/ajnr.a3567}, url = {}, year = 2013, month = {jun}, publisher = {American Society of Neuroradiology ({ASNR})}, volume = {34}, number = {11}, pages = {2113--2118}, author = {F. Miyoshi and T. Ogawa and S.- i. Kitao and M. Kitayama and Y. Shinohara and M. Takasugi and S. Fujii and T. Kaminou}, title = {Evaluation of Parkinson Disease and Alzheimer Disease with the Use of Neuromelanin {MR} Imaging and 123I-Metaiodobenzylguanidine Scintigraphy}, journal = {American Journal of Neuroradiology} }


3iodobenzylguanidine, aged, aged, 80 and over, alzheimer disease, and, brain, diagnosis, diagnostic use, disease, female, humans, magnetic resonance imaging, male, melanins, metabolism, methods, middle aged, molecular imaging, parkinson disease, pathology, pharmacokinetics, progression, radionuclide imaging, radiopharmaceuticals, reproducibility of results, sensitivity and specificity, tissue distribution

Countries of Study


Types of Dementia

Alzheimer’s Disease, Parkinson’s Dementia

Types of Study

Before and After Study

Type of Outcomes


Type of Interventions

Diagnostic Target Identification

Diagnostic Targets

Neuroimaging (e.g. MRI, PET, CAT etc.)